| By Noah Higgins-Dunn Biogen didn't just win the most closely watched FDA green light of the year. It snagged a "shockingly broad" label, set an aggressive $56,000 price and now stands poised for "one of the biggest drug launches in biopharma history," analysts say. The upshot? $10 billion in peak sales—or more. read more |
| |
|---|
|
| By Beth Snyder Bulik Physicians around the country are reporting sky-high patient demand for Biogen and Eisai's newly approved Alzheimer drug Aduhelm. While that's not surprising, what may be less expected is that doctors are ready to prescribe—despite debatable clinical trial results. read more |
| |
|---|
|
| By Annalee Armstrong The FDA seems to have set a new regulatory standard with its approval of Biogen’s aducanumab, now known as Aduhelm, in Alzheimer’s disease under an accelerated review pathway. So now what? Pharmaceutical companies and biotechs are surely asking this question in the aftermath of the controversial approval. read more |
| |
|---|
|
| By Paige Minemyer Shortly after its controversial Alzheimer's drug secured Food and Drug Administration approval on Monday, Biogen announced that it is already securing partnerships with major payers to ensure patients can access the drug. read more |
| |
|---|
|
| By Paige Minemyer CMS should act quickly on determining coverage for Biogen's newly approved Alzheimer's therapy, aducanumab, experts say. read more |
| |
|---|
|
| By Noah Higgins-Dunn The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. What's next? A ripple effect across Alzheimer's research, more controversy for the FDA and an all-out launch effort at Biogen, which really needs the sales boost. read more |
| |
|---|
|
| By Kyle LaHucik The FDA's approval of aducanumab set in motion a positive ripple effect for Biogen's publicly traded Alzheimer's treatment competitors, including Eli Lilly, which recently posted data on its own candidate, donanemab. read more |
| |
|---|
|
|
|
